Quick Answer
HARVARD BIOSCIENCE INC reported Total Revenue of $86.55 million for fiscal year 2025.
HARVARD BIOSCIENCE INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $86.55M -8.1% |
$94.14M -16.1% |
$112.25M -1.0% |
$113.33M -4.7% |
$118.90M +16.5% |
$102.10M -12.1% |
| Revenue (ASC 606) | $86.55M -8.1% |
$94.14M -16.1% |
$112.25M -1.0% |
$113.33M -4.7% |
$118.90M +16.5% |
$102.10M -12.1% |
| Net Income | -$56.70M -357.1% |
-$12.40M -263.3% |
-$3.42M +64.1% |
-$9.52M -3204.2% |
-$288.0K +96.3% |
-$7.81M -66.6% |
| Diluted EPS | — | — | — | — | — | — |
| Total Assets | $80.07M -36.8% |
$126.64M -7.8% |
$137.37M -5.5% |
$145.36M -10.5% |
$162.34M +3.9% |
$156.25M -5.2% |
| Cash and Equivalents | $8.61M +109.7% |
$4.11M -4.1% |
$4.28M -5.0% |
$4.51M -42.4% |
$7.82M -6.0% |
$8.32M -0.2% |
| Long-Term Debt | $35.87M | $0.00 -100.0% |
$30.70M -28.6% |
$43.01M -4.6% |
$45.09M -2.6% |
$46.29M -1.3% |
| Stockholders Equity | $13.73M -78.3% |
$63.34M -13.3% |
$73.07M +1.2% |
$72.22M -13.4% |
$83.40M +8.8% |
$76.68M -6.1% |
| R&D Expense | $8.82M -15.2% |
$10.41M -11.5% |
$11.76M -4.6% |
$12.33M +14.2% |
$10.80M +24.3% |
$8.69M -18.9% |
| Operating Income | -$48.58M -682.2% |
-$6.21M -427.9% |
$1.89M +127.3% |
-$6.93M -435.6% |
$2.07M +834.8% |
$221.0K -41.4% |
| Gross Profit | $49.91M -8.9% |
$54.77M -17.1% |
$66.07M +8.6% |
$60.82M -10.1% |
$67.65M +16.6% |
$58.04M -9.8% |
| Shares Outstanding | 44.72M +1.5% |
44.07M +1.6% |
43.39M +3.1% |
42.08M +2.3% |
41.14M +4.4% |
39.41M +3.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $20.59M | -6.3% | +0.7% |
| Revenue (ASC 606) | September 30, 2025 | $20.59M | -6.3% | +0.7% |
| Net Income | September 30, 2025 | -$1.23M | +74.4% | +46.1% |
| Diluted EPS | March 31, 2024 | -$0.11 | -1200.0% | -450.0% |
| Total Assets | September 30, 2025 | $77.99M | -40.6% | -2.6% |
| Cash and Equivalents | September 30, 2025 | $6.82M | +49.2% | -8.4% |
| Long-Term Debt | September 30, 2024 | $34.25M | -2.9% | +7.2% |
| Stockholders Equity | September 30, 2025 | $14.07M | -78.5% | -10.6% |
| R&D Expense | September 30, 2025 | $2.13M | -16.9% | -2.6% |
| Operating Income | September 30, 2025 | $197.0K | +110.5% | +124.1% |
| Gross Profit | September 30, 2025 | $12.02M | -5.8% | +4.2% |
| Shares Outstanding | September 30, 2025 | 44.58M | +2.2% | +0.1% |
- HARVARD BIOSCIENCE INC reported Total Revenue of $86.55 million for fiscal year 2025.
- HARVARD BIOSCIENCE INC showed a decrease of -8.1% in Total Revenue compared to the prior fiscal year.
- HARVARD BIOSCIENCE INC reported Revenue (ASC 606) of $86.55 million for fiscal year 2025.
- HARVARD BIOSCIENCE INC showed a decrease of -8.1% in Revenue (ASC 606) compared to the prior fiscal year.
- HARVARD BIOSCIENCE INC reported Net Income of -$56.70 million for fiscal year 2025.
- HARVARD BIOSCIENCE INC showed a decrease of -357.1% in Net Income compared to the prior fiscal year.
- HARVARD BIOSCIENCE INC reported Diluted EPS of $0.12 per share (loss) for fiscal year 2019.
- HARVARD BIOSCIENCE INC showed a decrease of -50.0% in Diluted EPS compared to the prior fiscal year.
- HARVARD BIOSCIENCE INC reported Total Assets of $80.07 million for fiscal year 2025.
- HARVARD BIOSCIENCE INC showed a decrease of -36.8% in Total Assets compared to the prior fiscal year.
- HARVARD BIOSCIENCE INC reported Cash and Equivalents of $8.61 million for fiscal year 2025.
- HARVARD BIOSCIENCE INC showed an increase of +109.7% in Cash and Equivalents compared to the prior fiscal year.
- HARVARD BIOSCIENCE INC reported Long-Term Debt of $35.87 million for fiscal year 2025.
- HARVARD BIOSCIENCE INC reported Stockholders Equity of $13.73 million for fiscal year 2025.
- HARVARD BIOSCIENCE INC showed a decrease of -78.3% in Stockholders Equity compared to the prior fiscal year.
- HARVARD BIOSCIENCE INC reported R&D Expense of $8.82 million for fiscal year 2025.
- HARVARD BIOSCIENCE INC showed a decrease of -15.2% in R&D Expense compared to the prior fiscal year.
- HARVARD BIOSCIENCE INC reported Operating Income of -$48.58 million for fiscal year 2025.
- HARVARD BIOSCIENCE INC showed a decrease of -682.2% in Operating Income compared to the prior fiscal year.
- HARVARD BIOSCIENCE INC reported Gross Profit of $49.91 million for fiscal year 2025.
- HARVARD BIOSCIENCE INC showed a decrease of -8.9% in Gross Profit compared to the prior fiscal year.
- HARVARD BIOSCIENCE INC reported Shares Outstanding of 44.72 million shares for fiscal year 2025.
- HARVARD BIOSCIENCE INC showed an increase of +1.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: